KAI Pharmaceuticals, Inc. Announces Advancement of KAI-4169 Clinical Program into a Phase 2 Trial

Published: Mar 14, 2011

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD). The Phase 2 study is a double-blind, randomized, placebo-controlled, multiple ascending dose study to assess the safety, tolerability and efficacy of multiple intravenous (IV) doses of KAI-4169 administered during hemodialysis in patients with SHPT.

Back to news